727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

• Jing Hua,
• Ricard Masia,
• Simon Turcotte,
• John Stagg,
• Jonathan Hill,
• Matthew Rausch,
• Devapregasan Moodley,
• Marisa Peluso,
• Secil Koseoglu,
• Gege Tan,
• Benjamin Lee,
• Isabelle Cousineau

Affiliations

Jing Hua

1Surface Oncology, Inc., Cambridge, MA, USA

Ricard Masia

1Surface Oncology, Inc., Cambridge, MA, USA

Simon Turcotte

Aff2 Université de Montréal, and Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal Quebec United States

John Stagg

Aff149 CRCHUM Montréal PQ Canada

Jonathan Hill

Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Keele, Staffordshire, UK

Matthew Rausch

1Surface Oncology, Inc., Cambridge, MA, USA

Devapregasan Moodley

1Surface Oncology, Inc., Cambridge, MA, USA

Marisa Peluso

1Surface Oncology, Inc., Cambridge, MA, USA

Secil Koseoglu

1Surface Oncology, Inc., Cambridge, MA, USA

Gege Tan

1Surface Oncology, Inc., Cambridge, MA, USA

Benjamin Lee

1Surface Oncology, Inc., Cambridge, MA, USA

Isabelle Cousineau

2Université de Montréal, Montreal, Canada